Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
| ▸ | CPT1A | P50416 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 3/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730295 | 0.83 | HDAC8 (0.46) | — | |
| SCHEMBL29798802 | 0.83 | HDAC8 (0.46) | — | |
| SCHEMBL17559354 | 0.81 | ACE (0.46) | POLBTDP1L3MBTL1DRD2 | |
| SCHEMBL5243620 | 0.81 | ACE (0.46) | POLBTDP1L3MBTL1DRD2 | |
| SCHEMBL3898933 | 0.81 | ACE (0.46) | POLBTDP1L3MBTL1DRD2 | |
| SCHEMBL2731004 | 0.81 | BCL2 (0.41) | POLBNAMPTHSD17B3TDP1L3MBTL1 | |
| SCHEMBL17559392 | 0.78 | NAMPT (0.39) | POLBNAMPTAKR1C3DPP4FAP | |
| SCHEMBL29098332 | 0.75 | ABHD6 (0.39) | POLBTDP1L3MBTL1 | |
| SCHEMBL2730312 | 0.74 | PTPN1 (0.50) | POLBHSD17B3TDP1L3MBTL1MMP8 | |
| SCHEMBL13892490 | 0.72 | DPP4 (0.47) | NAMPTHSD17B3AKR1C3CPT2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3719024-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | MARS, INCORPORATED | 2020-08-06 | — | — | US | disclosed |
| CN-106008569-B9 | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-05-22 | — | — | CN | disclosed |
| EP-3034509-B1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS INC (US) | 2020-04-22 | — | — | EP | disclosed |
| CN-106008569-B | Borate as arginase inhibitor and composition and application thereof | 马尔斯公司 | 2020-04-03 | — | — | CN | disclosed |
| US-10603330-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2019-02-21 | — | — | US | disclosed |
| US-10098902-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2018-10-16 | — | — | US | disclosed |
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2017-01-05 | — | — | US | disclosed |
| US-9440995-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-09-13 | — | — | US | disclosed |
| EP-3034509-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | Mars, Incorporated (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2632927-B1 | BORONATES AS ARGINASE INHIBITORS | MARS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| EP-2632927-A1 | BORONATES AS ARGINASE INHIBITORS | Mars, Incorporated (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| WO-2012058065-A1 | BORONATES AS ARGINASE INHIBITORS | MARS INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389464-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | POLB 1977/4885NAMPT 2147/4885HSD17B3 3182/4885 |
| US-10603330-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | POLB 1977/4885NAMPT 2147/4885HSD17B3 3182/4885 |
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | POLB 1977/4885NAMPT 2147/4885HSD17B3 3182/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | POLB 1977/4885NAMPT 2147/4885HSD17B3 3182/4885 |
| US-20200246362-A1 | Arginase Inhibitors as Therapeutics | ARG1, ARG2, PRMT1 | POLB 1977/4885NAMPT 2147/4885HSD17B3 3182/4885 |
| US-10098902-B2 | Arginase inhibitors as therapeutics | ARG1, ARG2, PRMT1 | POLB 1977/4885NAMPT 2147/4885HSD17B3 3182/4885 |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | POLB 1977/4885NAMPT 2147/4885HSD17B3 3182/4885 |
| US-20190054101-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | POLB 1977/4885NAMPT 2147/4885HSD17B3 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.